ORGS · As filed with the SEC
Orgenesis cash flow statement, by fiscal year
The statement as Orgenesis presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 | FY2018 Year ended Nov 30, 2018 | FY2017 Year ended Nov 30, 2017 |
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | — | — | — | — | — | — | — | (12,367) |
| Profit or Loss | (49,013) | (64,918) | (12,169) | (18,059) | 579 | (26,041) | (19,104) | — |
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||||||||
| Stock-Based Compensation Expense | 3,194 | 463 | 982 | 1,745 | 2,847 | 3,057 | 4,364 | 3,364 |
| Stock-based compensation for strategic collaborations | — | — | — | — | — | 2,641 | — | — |
| Stock-based compensation for Tamir Purchase Agreement (See Notes 4) | — | — | — | — | 17,048 | — | — | — |
| Capital gain, net | — | — | (170) | 25 | 22 | (29) | — | — |
| Share in losses of associated company | — | — | — | — | — | — | 731 | 1,214 |
| Gain on disposal of subsidiaries | — | — | — | — | (96,918) | — | — | — |
| Share in loss (income) of associated company | — | — | — | 272 | (106) | — | — | — |
| Convertible loans induced conversion expenses | 4,304 | — | — | — | — | — | — | — |
| Capital gain, net | (1,580) | — | — | — | — | — | — | — |
| Loss (gain) from deconsolidation of OBI, Korea and Belgium subsidiaries in 2024 (Octomera in 2023) | (4,480) | 5,343 | — | — | — | — | — | — |
| Share in loss of associated companies, net | 8 | 734 | 1,508 | — | — | — | — | — |
| Depreciation Expense | 2,086 | 1,560 | 1,978 | 1,864 | 1,435 | 3,806 | 2,624 | 2,598 |
| Net gain on remeasurement of previously equity interest in Atvio and CureCell to acquisition date at fair value | — | — | — | — | — | — | (4,509) | — |
| Change in fair value of warrants and embedded derivatives | — | — | — | — | — | — | 26 | (826) |
| Change in fair value of convertible bonds | — | — | — | — | — | — | 0 | (192) |
| Net changes in operating leases | — | — | — | — | — | (339) | — | — |
| Credit loss on convertible loan receivable | — | 2,688 | — | — | — | — | — | — |
| Impairment of investment | — | 699 | — | — | — | — | — | — |
| Credit loss net related to OBI, Korea and Belgium subsidiaries | 2,049 | — | — | — | — | — | — | — |
| Amortization of Intangibles | 18,338 | — | 1,061 | — | — | — | — | — |
| Effect of exchange differences on inter-company balances | 2,447 | 227 | 502 | 341 | (618) | — | — | — |
| Net changes in operating leases | 1,588 | (50) | (61) | (4) | 14 | — | — | — |
| Interest Expense | — | — | 1,372 | 482 | 927 | 387 | 2,564 | 1,110 |
| Change in Contingent consideration | (4,643) | — | — | — | — | — | — | — |
| Interest expense accrued on loans and convertible loans | 1,538 | 1,508 | — | — | — | — | — | — |
| Loss from extinguishment in connection with convertible loan restructuring | 5,422 | 283 | 52 | 1,865 | — | — | — | 0 |
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 130 | 30,060 | (21,051) | (12,178) | (1,350) | (5,308) | (2,901) | 33 |
| Prepaid expenses, other accounts receivable | 2,262 | 432 | 391 | (173) | (1,073) | — | — | — |
| Inventory | 34 | (389) | (7) | 55 | (84) | (414) | (931) | (265) |
| Decrease (increase) in other assets | — | — | 26 | (18) | (24) | (46) | (19) | (3) |
| Effect of exchange differences on inter-company balances | — | — | — | — | — | 214 | — | — |
| Decrease (increase) in prepaid expenses, other accounts receivable | — | — | — | — | — | (112) | 380 | (107) |
| Change in related parties, net | — | — | — | — | — | — | (532) | (583) |
| Other assets | 43 | 13 | — | — | — | — | — | — |
| Related parties, net | (2) | (439) | — | — | — | — | — | — |
| Accounts payable | (1,279) | 5,516 | (1,321) | (3,755) | 1,985 | 4,626 | (796) | (933) |
| Increase (decrease) in accrued expenses and other payable | — | — | — | — | — | 271 | 428 | 92 |
| Increase (decrease) in employee and related payables | — | — | — | — | — | 474 | (105) | 1,142 |
| Change in Deferred Revenue | — | — | — | — | — | — | 1,309 | 1,044 |
| Increase (decrease) in accrued expenses and other payable | — | — | — | — | (1,156) | — | — | — |
| Change in Accrued Liabilities | (820) | 1,013 | 1,570 | (248) | — | — | — | — |
| Change in Accrued Liabilities | 1,300 | 411 | (216) | 487 | (170) | — | — | — |
| Change in Deferred Revenue | — | — | 10 | — | (166) | 3,536 | — | — |
| Change in advance payments and receivables on account of grant, net | — | — | — | — | — | (247) | (193) | 2,156 |
| Increase (decrease) in deferred taxes | — | — | — | — | — | 304 | 982 | (1,310) |
| Change in advance payments and receivables on account of grant, net | — | — | — | — | 140 | — | — | — |
| Change in advance payments and receivables on account of grant, net | — | — | 722 | 433 | — | — | — | — |
| Deferred taxes, net | (2) | 9 | (103) | — | (1,378) | — | — | — |
| Net cash used in operating activities | (17,076) | (14,837) | (24,924) | (26,866) | (78,046) | (13,220) | (15,682) | (3,833) |
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Increase in loan to JV partner, a related party | — | — | — | — | (500) | (1,500) | (1,000) | — |
| Acquisition of CureCell, net of cash acquired | — | — | — | — | — | — | 58 | — |
| Acquisition of Atvio, net of cash acquired | — | — | — | — | — | — | 245 | — |
| Repayment of convertible loan to related party partners | — | — | 538 | — | — | — | — | — |
| Decrease in loan to associate entities | — | 55 | — | — | — | — | — | — |
| Increase in loan to associate entities | — | — | (4,131) | — | — | — | — | — |
| Loan granted | — | — | — | (818) | — | — | — | — |
| Net Cash from Financing Activities | — | — | 782 | — | 3,000 | — | — | — |
| Investment in convertible loan to related party | — | — | — | (3,000) | — | — | — | — |
| Loan to associate | — | — | — | (430) | — | — | — | — |
| Proceeds from Sale of PP&E | — | — | 246 | — | 7 | 79 | — | — |
| Purchase of property, plants and equipment | (263) | (2,096) | (12,416) | (7,866) | (1,525) | (12,129) | (5,556) | (975) |
| Long-term deposits | — | — | — | — | — | (228) | (15) | — |
| Acquisition of Koligo, net of cash acquired (See Note 4) | — | — | — | — | (955) | — | — | — |
| Proceed from sale of subsidiaries, net | — | — | — | — | 105,634 | — | — | — |
| Investment in associated company | — | — | — | — | (69) | — | — | — |
| Investment in associated company | — | (660) | — | (242) | — | — | — | — |
| Investment in deposits | — | — | — | (28) | — | — | — | — |
| Repayment from deposits | — | — | — | — | 18 | — | 0 | (2,429) |
| Net Cash from Investing Activities | 139 | — | 702 | — | — | — | — | — |
| Impact to cash resulting from deconsolidation of OBI, Korea and Belgium subsidiaries (see note 20) | (11) | (973) | — | — | — | — | — | — |
| Increase in cash from business combinations of TLABS and Orgenesis Austria | — | — | 160 | — | — | — | — | — |
| Investment in long-term deposits | — | (33) | (14) | — | — | — | — | — |
| Investment in long-term deposits | 500 | — | — | — | — | — | — | — |
| Net cash used in investing activities | 365 | (3,707) | (14,133) | (12,384) | 105,610 | (13,778) | (6,268) | (3,404) |
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Short-term line of credit | — | — | — | — | — | — | 0 | (21) |
| Repurchase of treasury stock | — | — | — | — | (250) | — | — | — |
| Repurchase of treasury stock | — | — | — | (1,016) | — | — | — | — |
| Proceeds from issuance of shares due to exercise of options and warrants (net of transaction costs) | 2,556 | 5,283 | 2,181 | 1,926 | 8,738 | — | — | — |
| Proceeds from Debt Issuance | 75 | 5,735 | 19,150 | — | 250 | 11,400 | 1,912 | 5,899 |
| Proceeds from Debt Issuance | — | — | — | — | — | 270 | — | — |
| Repayment of short and long-term debt | — | — | — | — | — | — | — | (1,108) |
| Proceeds from Stock Issuance | — | 5,000 | 20,000 | — | — | 13,200 | — | — |
| Proceeds from issuance of shares and warrants (net of transaction costs) | — | — | — | — | — | — | 17,392 | 5,297 |
| Loans received | — | — | — | — | — | — | — | 0 |
| Redeemable non-controlling interest | — | — | — | — | — | — | 14,058 | 2,349 |
| Proceeds from receipts on account of shares to be allotted | — | — | — | — | — | — | 2,252 | — |
| Repayment of convertible loans and convertible bonds | — | (3,000) | (2,300) | (1,000) | (2,400) | — | (177) | (4,051) |
| Repayment of short and long-term debt | (226) | (35) | (46) | (16) | (457) | (772) | (377) | — |
| Proceeds from issuance of loans payable | 6,060 | 635 | — | — | — | — | — | — |
| Proceeds from Debt Issuance | 774 | — | 1,396 | — | — | — | — | — |
| Transfer of the grant received to third party | — | — | (803) | — | — | — | — | — |
| Receipt from Germfree (see note 13f) | 6,720 | — | — | — | — | — | — | — |
| Net cash provided by financing activities | 15,959 | 13,618 | 39,578 | (106) | 5,881 | 24,098 | 35,060 | 8,365 |
| NET CHANGE IN CASH AND CASH EQUIVALENTS | — | — | — | — | — | — | 13,110 | 1,128 |
| Effect of Exchange Rate on Cash | — | — | — | — | — | — | (173) | 1,497 |
| CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR | — | — | — | — | — | 16,456 | 3,519 | 891 |
| CASH, CASH EQUIVALENTS AND RESTRCITED CASH AT END OF YEAR | — | — | — | — | — | — | 16,456 | 3,519 |
| NET CHANGE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | (752) | (4,926) | 521 | (39,356) | 33,445 | (2,900) | — | — |
| EFFECT OF EXCHANGE RATE CHANGES ON CASH ANDCASH EQUIVALENTS | — | — | — | — | — | (58) | — | — |
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR | — | — | — | — | 12,041 | 14,999 | — | — |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR | — | — | — | — | — | 12,041 | — | — |
| Effect of Exchange Rate on Cash | (40) | 36 | (126) | (238) | 82 | — | — | — |
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF YEAR | 1,479 | 6,369 | 5,974 | 45,568 | 12,041 | — | — | — |
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF YEAR | 687 | 1,479 | 6,369 | 5,974 | 45,568 | — | — | — |
| SUPPLEMENTAL NON-CASH FINANCING AND INVESTING ACTIVITIES | ||||||||
| Finance Leases of property, plant and equipment | — | — | — | — | 366 | — | — | — |
| Right-of-use assets acquired in exchange for right-of-use liabilities | — | — | — | — | 967 | — | — | — |
| Purchase of property, plant and equipment included in accounts payable | — | — | — | 331 | 241 | — | — | — |
| Net Cash from Operating Activities | — | — | — | — | — | 546 | — | — |
| Receivable from GPP | — | — | — | — | — | — | 6,600 | — |
| SUPPLEMENTAL INFORMATION ON INTEREST PAID IN CASH | — | — | — | — | — | — | 0 | 903 |
| Acquisition of other asset in exchange for common stocks | — | — | — | — | 700 | — | — | — |
| Issuance of common stocks in connection with the acquisition of Koligo | — | — | — | — | 11,172 | — | — | — |
| Recognition of finance lease liability and right-of-use assets | — | — | 136 | — | — | — | — | — |
| Recognition of operating lease liability and right-of-use assets | — | — | 432 | — | — | — | — | — |
| Net Cash from Operating Activities | 16,007 | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | 405 | 752 | — | — | — | 8,229 | — | — |
| Purchase of property, plant and equipment included in accounts payable | — | — | — | — | — | 1,584 | — | — |
| Finance Leases of property, plant and equipment | — | — | — | — | — | 355 | 955 | — |
| Increase (decrease) in accounts payable related to purchase of property, plant and equipment | — | 14 | (383) | — | — | — | — | — |
| Loan conversion for Redeemable non-controlling interest (See note 3) | — | — | 10,203 | — | — | — | — | — |
| Issuance of common stocks in connection with the acquisition of Mida | — | — | 100 | — | — | — | — | — |
| Extinguishment in connection with convertible loan restructuring | — | — | — | 1,848 | — | — | — | — |
| Extinguishment in connection with convertible loan restructuring | 5,281 | 287 | 226 | — | — | — | — | — |
| CASH PAID DURING THE YEAR FOR: | ||||||||
| Interest Expense | 4 | 785 | 458 | — | — | 157 | — | — |
| Income taxes, net of refunds paid in cash during the year | — | — | — | — | — | 156 | — | — |
| Conversion of principal amount and accrued interest of convertible loans and bonds to common stock and warrants | — | — | — | — | — | — | 7,511 | 1,277 |
| Reclassification of redeemable non-controlling interest to equity | — | — | — | — | — | — | — | 0 |
| Classification of loan receivable into services to be received from CureCell | — | — | — | — | — | — | 836 | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.